Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 168,664 shares of the biopharmaceutical company’s stock, valued at approximately $50,773,000. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.13% of Alnylam Pharmaceuticals at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. MV Capital Management Inc. purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter worth about $25,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at about $29,000. HM Payson & Co. acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $27,000. Golden State Wealth Management LLC grew its position in shares of Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 36 shares in the last quarter. Finally, Manchester Capital Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 600.0% during the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 72 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
ALNY has been the subject of a number of recent research reports. BMO Capital Markets began coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday. They issued an “outperform” rating and a $318.00 price target for the company. Sanford C. Bernstein raised shares of Alnylam Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, July 29th. Bank of America reduced their price objective on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a report on Tuesday, July 14th. Chardan Capital reaffirmed a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, July 31st. Finally, Stifel Nicolaus lowered their target price on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $386.62.
Insider Activity at Alnylam Pharmaceuticals
In related news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the transaction, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. This trade represents a 70.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by company insiders.
Alnylam Pharmaceuticals Stock Performance
Shares of ALNY opened at $242.61 on Thursday. The company has a market capitalization of $32.46 billion, a price-to-earnings ratio of 45.09 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 52-week low of $197.81 and a 52-week high of $495.55. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. The stock has a 50 day moving average price of $269.15 and a 200 day moving average price of $298.51.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. The company had revenue of $1.29 billion for the quarter, compared to analysts’ expectations of $1.32 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The firm’s revenue for the quarter was up 66.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.51) earnings per share. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current fiscal year.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.
Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.
Featured Stories
- Five stocks we like better than Alnylam Pharmaceuticals
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
